ProHealth health Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

10 Fibro-Friendly Foods with a Bonus: Beautiful Skin

Fight Back! Win the War Being Waged Against Your Immune System

The role of microbiota and intestinal permeability in the pathophysiology of autoimmune and neuroimm...

Studies Show that Magnesium L-threonate Improves Brain Plasticity, Leading to Direct and Significant...

Clary Sage Oil May Be Pricey, but Its Benefits Are Priceless

Component of red wine, grapes can help to reduce inflammation, study finds

Poly MVA: A Novel Therapy for Increasing Energy, Repairing DNA, and Promoting Overall Health

Acupressure reduced fatigue in breast cancer survivors

Omega-3 fatty acid stops known trigger of lupus

What’s Fenugreek Good For?

Print Page
Email Article

UT Southwestern, M.D. Anderson Researchers Identify Lung-Cancer Tumor Suppressor Genes

  [ 19 votes ]   [ Discuss This Article ] • April 30, 2002

Researchers at The University of Texas M. D. Anderson Cancer Center and The University of Texas Southwestern Medical Center at Dallas have identified three lung-cancer tumor suppressor genes on chromosome 3 that dramatically reduced human lung cancer growth in mice and for which gene therapy trials with humans will begin within a year.

Researchers at both UT institutions, working under a joint National Cancer Institute Specialized Program of Research Excellence (SPORE) in Lung Cancer grant, published their findings in the May 1 issue of Cancer Research.

Dr. John Minna, senior author of the study, director of the Nancy B. and Jake L. Hamon Center for Therapeutic Oncology Research at UT Southwestern and principal investigator for the UT SPORE in Lung Cancer, said this research has been under way for 10 years. Working from a set of about 20 genes previously identified as possible tumor suppressors, UT Southwestern researchers homed in on a small region of chromosome 3, where they identified eight possible tumor-suppressor genes.

Under the direction of Dr. Jack Roth, chairman of the Department of Thoracic and Cardiovascular Surgery at M. D. Anderson and co-principal investigator for the UT SPORE in Lung Cancer, M. D. Anderson researchers tested six of the genes’ effectiveness as tumor suppressors using their new adenovirus technology. They found three genes – 101F6, NPRL2 and FUS1 – that not only inhibited tumor growth and metastasis, but induced human lung cancer cell death.

Dr. Roth said the discovery of this chromosomal 3p region is the earliest genetic change detected in the process of lung cancer development. The significance of the finding could be far-reaching, he said, with greater opportunity for earlier detection, diagnosis, prevention and treatment of lung cancer.

“Discovering a region on a chromosome, as opposed to a single gene, that contributes to cancer development is novel,” said Dr. Roth. “This is the earliest genetic change yet identified in lung cancer, a change that can take place in normal-looking lung tissue.”

Dr. Minna, who also directs the W.A. “Tex” and Deborah Moncrief Jr. Center for Cancer Genetics, said, “We saw that the 3p genes triggered apoptosis, the natural process of cell death, in cancer cells. But putting the same genes in normal human lung epithelial cells didn’t kill those cells.”

The 3p genes were used to treat human lung cancers growing in mice, and the treatment caused a dramatic regression of the tumors, Dr. Minna said. The researchers also introduced cancer systemically – injecting malignant cells intravenously into mice and allowing them to form tumors around the body as metastases – then introduced the 3p gene therapy in the same fashion. They found that the systemic therapy also was effective in reducing the metastatic tumors. A virus genetically engineered to be harmless was used to deliver the genes.

“We used Dr. Roth’s adenovirus,” Dr. Minna said. “There was no toxicity, and it looks like we can deliver enough tumor suppressor genes to cure the mice.”

One of the genes pinpointed in the study, FUS1, will be brought forward into a Phase I clinical trial led by Dr. Roth, a world leader in gene therapy of lung cancer and director of the W. M. Keck Center for Cancer Gene Therapy at M. D. Anderson. The clinical trial, recently approved by the National Institutes of Health Recombinant DNA Advisory Committee, will be conducted jointly at M. D. Anderson and UT Southwestern. In that trial, expected to start in about six months to a year, patients with lung cancers will receive the gene therapy, delivered in a lipid “capsule” that is injected and binds to tumors in the body.

“This study, another productive collaboration with Dr. Minna and his team at UT Southwestern, is an excellent example of translational research,” Dr. Roth said. “The team in Dallas identified the region on the chromosome, while the M. D. Anderson group analyzed the function of the genes, and together we are using the information to develop and improve treatment strategies for patients.”

The collaboration between lung-cancer researchers at M. D. Anderson and UT Southwestern began in 1996 when the joint program was awarded a $4.5 million SPORE grant from the NCI to accelerate research and improve therapy for lung cancer.

Other researchers from M. D. Anderson who contributed to the study include lead author Dr. Lin Ji, Dr. Masahiko Nishizaki, Dr. Kai Xu, Dr. Nancy Yen, Dr. E. Neely Atkinson and Dr. Bingliang Fang. Other UT Southwestern researchers contributing to the study were Dr. Boning Gao, Dr. David Burbee, Dr. Masashi Kondo, and Dr. Craig Kamibayashi. Dr. Michael Lerman from the NCI also contributed to the research.

In addition to the NCI, the research was supported by Tenneco, Exxon, Tobacco Settlement Funds, a W. M. Keck Gene Therapy Career Development Grant and Introgen Therapeutics.

Post a Comment

Featured Products From the ProHealth Store
Optimized Curcumin Longvida® Energy NADH™ 12.5mg Ultra EPA  - Fish Oil

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments

Be the first to comment on this article!

Post a Comment

Natural Pain Relief Supplements

Featured Products

FibroSleep™ FibroSleep™
The All-in-One Natural Sleep Aid
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Optimized Curcumin Longvida® Optimized Curcumin Longvida®
Supports Cognition, Memory & Overall Health
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function

Natural Remedies

The Remarkable Benefits of Reishi Medicinal Mushrooms The Remarkable Benefits of Reishi Medicinal Mushrooms
Undenatured Type II Collagen - Chicken Soup for Your Joints Undenatured Type II Collagen - Chicken Soup for Your Joints
Fighting Fatigue with Ground-breaking French Oak Wood Extract Fighting Fatigue with Ground-breaking French Oak Wood Extract
Health Benefits Are Brewing in Green Tea Health Benefits Are Brewing in Green Tea
Vitamin E: Super Antioxidant We Only Thought We Knew Vitamin E: Super Antioxidant We Only Thought We Knew

ProHealth, Inc.
555 Maple Ave
Carpinteria, CA 93013
(800) 366-6056  |  Email

· Become a Wholesaler
· Vendor Inquiries
· Affiliate Program
Credit Card Processing
Be the first to know about new products, special discounts and the latest health news. *New subscribers only

CONNECT WITH US ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus

© 2016 ProHealth, Inc. All rights reserved. Pain Tracker App  |  Store  |  Customer Service  |  Guarantee  |  Privacy  |  Contact Us  |  Library  |  RSS  |  Site Map